|
|
||||||||


*
Center for Neurologic Diseases, Department of Neurology, and
Vascular Research Division, Department of Pathology, Brigham and Womens Hospital, Boston, MA 02115;
Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138; and
§
Department of Neurology, University of California, San Francisco, CA 94143
| Abstract |
|---|
|
|
|---|
-stimulation, primary and immortalized
astrocytes up-regulate class II transactivator (CIITA), invariant chain
(Ii) (p31 and p41), H-2Ma, and H-2Mb. Analysis of CIITA cDNA sequences
demonstrated that CIITA transcription in astrocytes is directed by a
promoter (type IV) that mediates IFN-
-inducible CIITA expression and
encodes a CIITA protein that differs in its N-terminal sequence from
CIITA reported in professional APC. Comparing live and fixed APC for Ag
presentation, we show that Ag processing by APC is required for
presentation of native MBP to autopathogenic T cells specific for the
major MBP epitope, Ac1-11. We have observed that primary astrocytes and
some, but not all, astrocyte lines in the absence of contaminating
microglia are capable of processing and presenting native MBP,
suggesting that there may be heterogeneity. Our study provides
definitive evidence that astrocytes are capable of processing CNS
autoantigen, indicating that astrocytes have potential for processing
and presentation of CNS autoantigen to proinflammatory T cells in CNS
autoimmune disease. | Introduction |
|---|
|
|
|---|
for class II expression (3, 4). Whether astrocytes participate in the
activation and regulation of CD4+ T cells within CNS
inflammatory conditions in vivo is not clear. In vitro, astrocytes
stimulated by IFN-
up-regulate class II as well as certain
costimulatory molecules and can present Ag to CD4+ T cells,
indicating that they are also capable of processing native CNS
autoantigens (3, 5, 6, 7). However, other data indicate that astrocytes
are not efficient in Ag presentation and T cell activation, suggesting
that they may be deficient in some element(s) necessary for Ag
presentation (8, 9, 10, 11, 12). Processing of native CNS autoantigen may be
required for initiating or perpetuating chronic activation of
encephalitogenic T cells in vivo.
Processing of Ag by APC for presentation to CD4+ T cells
occurs through the endocytic pathway, which requires the coordinate
regulation of molecules that participate in class II biosynthesis and
maturation (13). The class II transactivator (CIITA) is the key
intermediate responsible for constitutive and IFN-
-inducible
expression of class II (4). Recently, it was observed that CIITA
expression is controlled in a tissue-specific manner through the
differential activation of multiple nonhomologous promoters (14). One
specific promoter, the type IV promoter, directed CIITA transcription
in nonprofessional APC. Two other CIITA promoters were utilized in
professional APC, type I in dendritic cells and type III in B cells.
More recently, the type III promoter was shown to contain sequence(s)
that also confers IFN-
-inducible CIITA expression (15). CIITA also
directs expression of invariant chain (Ii) and H-2M (HLA-DM), two
molecules involved in class II maturation and Ag processing (16, 17).
Deficiency in any of these elements can result in defects in Ag
processing (18, 19, 20, 21).
In this study, Ag processing was examined in primary and immortalized
pure murine astrocyte lines. The latter offer several advantages,
providing a useful complement to studies involving primary astrocytes
(22, 23, 24). Immortalization by certain methods can capture astrocytes at
different stages of differentiation, allowing one to examine whether
there are developmental changes in their capability to serve as APC
(22, 23, 24, 25, 26). Generation of separate lines from one population of primary
astrocytes allows one to investigate whether there may be individual
variation. Moreover, immortalized astrocytes are not contaminated with
microglia, a more potent CNS APC, which can activate T cells in vitro
and in vivo (27). In fact, potential contamination with microglia is
regarded as an important concern when evaluating Ag presentation by
primary astrocytes (3, 5, 6, 7) and is also a concern when using sensitive
techniques for examining gene expression in primary astrocyte cultures.
By comparing live and fixed APC for their capability to present MBP, we
demonstrate that processing is required for presentation of native MBP
to encephalitogenic T cells that recognize the dominant MBP
determinant, Ac1-11. Our results show that IFN-
-stimulated
astrocytes utilize the type IV CIITA promoter and define for the first
time the protein sequence at the N terminus of the CIITA isoform
transcribed from the murine type IV CIITA. In this study, we provide
evidence that astrocytes express elements involved in the class II
endocytic pathway and are capable of processing native CNS autoantigen.
| Materials and Methods |
|---|
|
|
|---|
Primary glial cultures were prepared from cerebral hemispheres of newborn B10.PL (H-2u) mice as described (28). After removal of the meninges, dissociated tissue from the cerebral lobes was passed through a sterile 70-µm nylon cell strainer. This cell suspension was centrifuged, treated with trypsin-EDTA for 5 min at 37°C, washed, and plated in RPMI 1640 containing 10% heat-inactivated FCS, L-glutamine, and penicillin/streptomycin. Cells were initially plated at 5 x 104 cells/cm2 in 75-cm2 flasks that had been treated with poly-D-lysine (10 µg/ml) and washed 3 times. Nonadherent cells, including oligodendrocytes and microglia, were removed after 7 days of culture by agitation (200 rpm for 8 h). Supernatant was removed, media was replaced, and agitation was repeated (200 rpm for 18 h). Again, supernatant was removed and media was replaced. A total of 97% of the remaining cells were glial fibrillary acidic protein (GFAP)+ and <1% were Mac-1+.
Immortalization of primary astrocytes
The SV40-406 cell line produces a replication-defective retrovirus encoding the SV40 large T Ag in the pZipNeoSV(X)1 construct (22, 24), which also contains neomycin phosphotransferase (Neo). Astrocytes cultured in vitro were exposed to SV40-406 culture supernatants for 2 h in the presence of polybrene (4 µg/ml). After one or more days of treatment, cells were exposed to G418 (400 µg/ml). Astrocytes were immortalized from two separate astrocyte cultures. Three colonies were recovered from cells immortalized after 7 days, providing lines 3.1, 3.2, and 3.3. Two colonies were obtained from cells immortalized after 45 days in culture, providing lines 1.1 and 2.1. Each colony was recovered from a separate plate. Thus, each line was the result of a separate immortalization event. All lines are GFAP+, Mac-1- (a marker for microglia and macrophages), and negative for galactocerebroside (a marker for oligodendrocytes).
Antigens
MBP peptide Ac1-11 (ASQKRPSQRHG) was synthesized by solid-phase F-moc chemistry by Quality Control Biochemicals (Hopkinton, MA) and purified by reversed-phase HPLC (C18 column, YMC, Raleigh-Durham, NC). The major peak contained 95% desired product, as determined by MALDI-TOF mass spectrometry and HPLC. Native murine, bovine, and human MBP were purified as described (29).
MBP-specific T cells
PJR-25 is an encephalitogenic CD4+ Th1 cell clone derived from PL/J mice (30) that is specific for MBP Ac1-11 in association with I-Au. PJR-25 recognizes intact mouse, bovine, guinea pig, and human MBP.
Proliferation assays
APC were treated with mitomycin C (60 µg/ml) for 1 h and washed three times with media. T cells (104/well) were cultured with either peptide or intact MBP and APC (4 x 104/well) in a 96-well microtiter plate. In Ag fixation experiments, APC were treated with 0.5% paraformaldehyde for 30 min at room temperature and washed three times with media. APC were co-cultured with T cells in the presence of either peptide or intact Ag. All cultures were incubated for 48 h at 37°C. [3H]Thymidine (1 µCi/ml) was added 18 h before harvesting and counting.
Flow cytometry
After culture alone or with IFN-
(100 U/ml) for 48 h,
astrocytes were removed from flasks by treatment with PBS-EDTA,
counted, dispensed at 106 cells/tube, and washed with FACS
buffer (PBS containing 0.5% BSA and 10 mM sodium azide). Cells were
stained with either mAb 10-2.16 (anti-I-Ak,u) (31) or
an isotype-matched control mouse Ab for 45 min at room temperature,
washed, then incubated with a FITC-labeled rat anti-mouse secondary
Ab for 45 min at room temperature. After three washes, samples were
analyzed on a FACSort (Becton Dickinson, CA).
mRNA analysis
mRNA was prepared from 1 x 108 cells using the Fast Track mRNA Isolation Kit (Invitrogen, San Diego, CA). Reverse transcription was performed using the GeneAmp RNA PCR Kit (Perkin-Elmer, Applied Biosystems, Foster City, CA) for 1 cycle: 42°C for 15 min, 99°C for 5 min, and 5°C for 5 min. The following PCR primers (designed from published sequences (14, 32, 33, 34)) were purchased from Genosys Biotechnologies (The Woodlands, TX): CIITA, 5'-CCCCTACATCTACCACCTCTAT-3' and 5'-CTCCCTTTCCTGGCTCTTGTTGCT-3'; CIITA type I promoter, 5'-AAGAAGGAGAAGGCTACA-3' and 5'-CTGGTCGCAGTTGATGGTAT-3'; CIITA type III promoter, 5'-GGCTGCCTGCTTCCCACC-3' and 5'-TCGGGGAGACTGGGGATACT-3'; CIITA type IV promoter, 5'-GCAGGCAGCACTCAGAAGCA-3' and 5'-CTGGTCGCAGTTGATGGTAT-3'; Ii exons 15, 5'-GGACCCCACAGGACTTCACATACT-3' and 5'-AGATGCTTCAGATTCTCTGG-3'; Ii exons 37, 5'-TGGCTACTCCCTTGCT-3' and 5'-TCCTGCCTGGTCACTC-3'; Ii exon 6b, 5'-AGTGCCAGGAAGAAGT-3' and 5'-TCTTGGTGTGAGGAAC-3'; H-2Ma, 5'-CTACGAGATGTTGATGCGGGAAGT-3' and 5'-GTGTAGCGGTCAATCTCGTGTGTC-3'; H-2Mb, 5'-GGACCCCACAGGACTTCACATACT-3' and 5'-GCCGTCTTCTCCTTGTTGCTGTGG-3'; ß-actin, 5'-CACCCTGTGCTGCTCACCGAGGCC-3' and 5'-CCACACAGATGACTTGCGCTCAGG-3'. For PCR detection of ß-actin, CIITA, H-2Ma, H-2Mb, and Ii exons 37, cDNA was amplified 35 cycles: 95°C, 15 s; 58°C, 30 s; and 72°C, 30 s. For detection of Ii exon 6b, cDNA was amplified 35 cycles: 94°C, 15 s; 69°C, 30 s; and 72°C, 30 s.
DNA sequencing
A 1.0 µl gel fragment containing the predominant 220-nucleotide (nt) cDNA band from electrophoresis of RT-PCR product was reamplified 10 cycles using the same parameters for initial PCR, then purified. DNA was sequenced using dideoxy-terminators on a Perkin-Elmer ABI 373 Stretch Sequencer.
Western blot analysis of Ii p31 and p41
Cells were solubilized in PHEM lysis buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2, and 1.0% Triton X-100 containing 1 mM PMSF, 1 mg/ml leupeptin, 20 mM benzamidine, and 5 mM iodoacetamide; pH 6.9), then centrifuged. Clarified supernatants were resolved by SDS-PAGE using 10% polyacrylamide gels under reducing conditions. Proteins were transferred to poly(vinylidene difluoride) membranes (Millipore, Bedford, MA), which were blocked for 90 min with 7.5% nonfat dry milk in TBS-Tween (TBS-T; 20 mM Tris, 137 mM NaCl, 0.1% Tween 20, pH 7.6). After three washes with TBS-T, membranes were incubated with primary rat mAb In-1 (35) diluted 1:10 in TBS-T for 90 min. Membranes were washed three times with TBS-T before addition of a horseradish peroxidase-conjugated goat anti-rat secondary Ab diluted 1:5000 in TBS-T. After 60 min incubation with the secondary Ab, membranes were washed five times with TBS-T. Ii proteins were then visualized by the enhanced chemiluminescent detection kit (ECL; Amersham, Arlington Heights, IL), followed by exposure to x-ray film.
| Results |
|---|
|
|
|---|
-inducible CIITA expressionFive individual astrocyte lines were obtained from immortalization of primary B10.PL (H-2u) astrocyte cultures using a replication defective retrovirus containing SV40 large T Ag in the pZipNeoSV(X)1 construct (see Materials and Methods). Immortalization by this method does not confer tumorigenicity (22). Astrocytes were immortalized from multiple separate primary astrocyte cultures. Three colonies were recovered from one primary culture immortalized after 7 days, providing lines 3.1, 3.2, and 3.3. Two colonies were obtained from separate primary cultures immortalized after 45 days, providing lines 1.1 and 2.1. All astrocyte lines express glial fibrillary acidic protein (GFAP), an intermediate filament protein expressed primarily by astrocytes. They do not express Mac-1, an Ag expressed on microglia or macrophages (data not shown).
CIITA is considered essential for the IFN-
-inducible expression of
class II, Ii, and H-2M (16, 17). RT-PCR was used to evaluate CIITA
expression in unstimulated and IFN-
-stimulated immortalized
astrocyte lines and primary astrocytes. As shown in Fig. 1
A, CIITA transcripts were not
detected by RT-PCR in unstimulated astrocyte lines or primary
astrocytes, but were present in all astrocyte lines and primary
astrocytes following stimulation with IFN-
.
|
-inducible CIITA expression (14). More recent studies indicate
that utilization of the type III CIITA promoter can be involved in
IFN-
-inducible CIITA expression (15). The CIITA transcripts directed
by the separate promoters differ at their 5' ends (exon 1). When RT-PCR
was performed with mRNA isolated from IFN-
-stimulated astrocyte
lines and primary astrocytes using 5' primers from transcribed
sequences of the type IV CIITA promoter and a 3' primer located within
the common CIITA coding sequence (32), CIITA expression was detected
(Fig. 1
The cDNA products from the RT-PCR performed on two immortalized
astrocyte lines and primary astrocytes (data presented in Fig. 1
B) using a 5' primer from the type IV CIITA promoter were
sequenced. The sequences from the two immortalized astrocyte lines and
primary astrocytes proved to be identical (Fig. 2
). The 3' end of the promoter sequence
is contiguous with the CIITA coding sequence, starting at nt 146, which
is 52 nt downstream of the AUG (start codon) used for initiating
CIITA translation in B cells. The next AUG (identified as "ATG" in
Fig. 2
), which is located within a perfect Kozak sequence for
initiation of translation (36), begins at nt 166. Initiation of
translation at this AUG potentially encodes a CIITA protein that has 24
or 101 fewer N-terminal amino acids than the CIITA encoded by B-cells
or dendritic cells, respectively (14). Thus, we define for the first
time the N-terminal protein sequence of the CIITA isoform
directed by the murine type IV CIITA promoter. Furthermore, our
results indicate that there are no additional undiscovered exons
containing N-terminal coding sequence transcribed from the type IV
CIITA promoter.
|
In Fig. 3
A, it can be
seen that all IFN-
-stimulated astrocytes up-regulated Ii mRNA. For
primary astrocytes and certain lines, constitutive and inducible Ii
mRNA was detected. APC can express two Ii isoforms, p31 and p41 (13, 33). Ii p41 differs by a 192-nt (64 amino acid) segment encoded by one
additional exon, 6b (33). Ii p31 is the predominant form in most cells
examined (13). Although Ii p31 and p41 both facilitate MHC class II
assembly and prevent premature peptide binding to class II molecules,
some data suggest that Ii p41 may also stabilize one or more proteases
in the Ag processing compartment (37, 38). Using primers from sequences
located within exon 6b, p41 mRNA was detected in IFN-
-stimulated
astrocytes (Fig. 3
A, second panel from top). Utilizing
primers that flanked exon 6b and distinguished p31 from p41
transcripts, both p31 and p41 transcripts were detected (Fig. 3
A, third panel from top).
|
-stimulated astrocyte lines
examined, as well as B10.PL splenocytes, expressed both Ii p31 and p41
proteins and that p31 is the predominant isoform (Fig. 3
. All of the immortalized astrocyte lines, including 3.3,
expressed significant levels of intracellular Ii protein by FACS
analysis (data not shown).
Astrocytes were examined for expression of H-2Ma and H-2Mb mRNA by
RT-PCR. In lines 3.3, 1.1, and 2.1, H-2Ma expression was primarily
inducible by IFN-
(Fig. 4
).
Constitutive H-2Ma expression was also observed in 3.1, 3.2, and
primary astrocytes. In all astrocyte lines and primary astrocytes,
stimulation with IFN-
caused up-regulation of H-2Mb expression.
|
Similar to primary astrocytes, the immortalized lines do not
express cell surface class II without stimulation with IFN-
(3, 7).
As shown by FACS analysis in Fig. 5
A, astrocyte lines and
primary astrocytes can express I-Au class II molecules
following stimulation with IFN-
. In several separate experiments, it
has been observed that line 3.2 expresses the lowest levels of
I-Au. Periodic re-examination over 1 yr has shown that each
pattern of IFN-
-inducible class II expression by individual lines
has not changed.
|
-stimulated astrocyte lines can
express elements involved in the class II endocytic pathway, the lines
were tested for their capability to present the immunodominant MBP
peptide Ac1-11 to encephalitogenic T cells that recognize this epitope
(30). Splenocyte APC were tested in parallel. APC were pretreated with
mitomycin C, which allowed APC to remain metabolically active but
incapable of cell division. Four of five IFN-
-stimulated astrocyte
lines could present MBP Ac1-11. Representative data are shown in Fig. 5
Three of the four lines that could present MBP Ac1-11 to MBP-specific T
cells could also present native MBP. Line 3.3, which could present
Ac1-11, was not capable of presenting native MBP (Fig. 5
C).
This line could not present any form of native MBP, including guinea
pig, mouse, bovine, or human MBP, although the other lines could
present these heterologous MBP proteins. Thus, of five lines tested,
three lines (1.1, 2.1, and 3.1) could present either native MBP or
Ac1-11, one line (3.3) could present only Ac1-11, and one line (3.2)
could not efficiently present Ac1-11 or native MBP. The inability to
present MBP Ac1-11 or native MBP by line 3.2 does not reflect the lack
of expression of costimulatory molecules. All lines express B7-2 (lines
1.1 and 2.1 can also express both B7-1 and B7-2 (data not shown),
and activation of these encephalitogenic T cells requires B7-2
costimulation (J.M.S. and S.S.Z., unpublished data). As described by
others (7), we have also observed that, in contrast to splenic APC
(39), increasing the number of astrocyte APC does not enhance
Ag-specific T cell proliferation.
Denatured Ag or partially degraded fragments of native Ag may not
require processing by APC for presentation to T cells (40, 41, 42). Our
observation that astrocyte line 3.3 presented MBP Ac1-11 but not native
MBP suggests that processing by APC is required when native MBP is used
as the Ag and that line 3.3 may possess a defect(s) in processing
native MBP. To establish clearly whether processing of native MBP is
necessary, we examined whether IFN-
-activated astrocytes fixed by
treatment with paraformaldehyde could present Ac1-11 and native MBP.
Primary astrocytes and splenocytes were also examined. When fixed with
paraformaldehyde, astrocyte lines could present MBP Ac1-11, but not
native MBP (Table I
). Similar to the
astrocyte lines, primary astrocytes fixed with paraformaldehyde could
only present Ac1-11, whereas primary astrocytes treated with
mitomycin C could present Ac1-11 or native MBP. These results
demonstrate that processing is required for presentation of native MBP
to T cells specific for MBP Ac1-11 and that some, but not all, of these
astrocytes are capable of Ag processing.
|
| Discussion |
|---|
|
|
|---|
One astrocyte line (3.3) was capable of presenting MBP peptide but not
native MBP, suggesting that it is deficient in some aspect(s) of
processing MBP. However, this line expressed CIITA, Ii, H-2M, and class
II after stimulation with IFN-
, demonstrating that although
expression of these elements may be necessary, it is not sufficient for
processing and presentation of the major encephalitogenic MBP
determinant. It was observed that, when melanoma cell lines deficient
in CIITA, class II, Ii, and HLA-DM (H-2M) were transfected with
CIITA, expression of all these elements was restored, although
transfected cells could only present peptide Ag (17, 46). Processing of
native Ag required exposure to IFN-
, suggesting that IFN-
induces
expression of another product(s) involved in Ag processing, independent
of CIITA. In this regard, other transactivating factors related to this
pathway may exist (47). Our observation that the IFN-
-stimulated
astrocyte line 3.3 is not capable of processing native MBP suggests
that 3.3 cells require expression of a factor(s) that is not dependent
upon IFN-
or that these cells are deficient in an aspect of IFN-
activation. Further analysis with these cells will permit examination
of other elements, including specific proteases (48, 49), that may be
required for MBP processing by astrocytes.
Astrocytes are not a uniform glial cell subpopulation (50, 51). Morphologic and biochemical characteristics have been used to distinguish astrocyte subtypes, suggesting that there may be functional heterogeneity (51, 52, 53). Some studies indicate that there may also be regional heterogeneity (52, 53). We have observed that three immortalized astrocyte lines (3.1, 3.2, and 3.3) isolated from the same primary culture differ from one another in their capability to present MBP, suggesting that there may be heterogeneity among individual astrocytes with regard to Ag presentation. We have also observed differences in expression of costimulatory molecules by murine astrocytes from one mouse strain (J.M.S. and S.S.Z., unpublished data). Thus, possible heterogeneity could, in part, account for the conflicting results reported regarding astrocyte function in T cell activation.
Immortalized astrocyte lines were used as a source of pure astrocytes, as primary astrocytes, in general, become senescent (23). Other investigators using this same approach to study CNS cells, including astrocytes, have also shown that immortalized cells retain important phenotypic characteristics of primary cells (22, 23, 24, 26). However, one concern in studying accessory cell function with immortalized astrocytes is that immortalization may confer properties not shared by primary astrocytes. For example, we cannot eliminate the possibility that deficiency in Ag processing by line 3.3 is related to its immortalization. However, we have shown that this astrocyte line, like primary astrocytes and astrocyte lines that do process and present MBP, is not deficient in expression of the elements addressed in this study, namely CIITA, Ii, H-2Ma, H-2Mb, or class II. If deficiency in a particular element involved in Ag processing is identified, it will be necessary to investigate whether immortalization, possibly by the integration within a particular gene locus, is related to deficient expression of that element. It is possible that interruption of gene expression by immortalization may facilitate the identification of additional genes involved in Ag processing. In this study, we have shown by examining immortalized astrocytes in parallel with primary astrocytes how immortalized astrocytes can serve as a valuable complement for the study of immune regulation by astroglia.
CIITA has been described as the "master control factor" for
regulation of expression of MHC class II molecules (4). Although not a
DNA-binding protein, CIITA is a transcriptional co-activator that
associates with the RFX family of DNA-binding proteins to form a
complex for activating class II gene transcription (54). Our results
demonstrate that CIITA expression in astrocytes is IFN-
-inducible
and that its transcription is directed by the type IV CIITA promoter
element. As it has recently been shown that distant promoter sequences
confer IFN-
inducibility to the type III CIITA promoter (15), it is
possible that this promoter element could be involved in regulation of
CIITA expression in astrocytes under conditions not used in this study.
Use of the type IV promoter produces a transcript encoding a CIITA
protein that differs at its N terminus from the CIITA molecules
expressed constitutively by professional APC (14). Analysis of the type
IV CIITA transcripts in astrocytes also indicates that there are no
additional exon-containing N-terminal coding sequences directed by the
type IV CIITA promoter in these cells. The potential for distinct
CIITA proteins that differ in N-terminal amino acid sequences raises
the question of whether there is another level of complexity regarding
CIITA expression in astrocytes and other nonprofessional APC. It is
also possible that polymorphism exists within regions of this promoter
element, which could contribute to class II dysregulation by
nonprofessional APC that participate in Ag presentation to pathogenic T
cells in organ-specific autoimmune disease, such as EAE and MS. It was
observed that IFN-
-stimulated astrocytes from certain mouse strains
resistant to EAE expressed lower levels of class II, suggesting a
correlation between the level of expression of class II by astrocytes
and susceptibility to EAE (55). In that study, the F1
progeny of susceptible and resistant strains were susceptible to EAE
and both parental class II alleles (haplotypes) were up-regulated,
suggesting that a transactivating factor, possibly located outside the
MHC, was deficient in the resistant parental strain. Thus, it will be
of interest to determine whether there is polymorphism within this
CIITA promoter and whether regulation of CIITA may contribute to
EAE and MS susceptibility. Furthermore, learning how to manipulate
expression of elements in the MHC class II endocytic pathway by CNS
accessory cells in vivo could be beneficial in the therapy for T
cell-mediated CNS autoimmune disease.
Note added in revision.
Since submission of this manuscript, two studies have been published that also address whether astrocytes are capable of processing native Ag (56, 57). The report by Tan et al. (56) indicates that astrocytes are capable of processing native Ag, whereas the study by Aloisi et al. (57) indicates that astrocytes are inefficient in processing and presentation of native Ag.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Scott S. Zamvil, Department of Neurology, C-440, University of California, 521 Parnassus Ave., San Francisco, CA 94143-0114; E-mail address: ![]()
3 Abbreviations used in this paper: CIITA, class II transactivator; CNS, central nervous system; EAE, experimental allergic encephalomyelitis; Ii, invariant chain; MBP, myelin basic protein; MS, multiple sclerosis; TBS-T, TBS-Tween; nt, nucleotide. ![]()
Received for publication March 20, 1998. Accepted for publication July 30, 1998.
| References |
|---|
|
|
|---|
. J. Mol. Cell. Immunol. 2:269.[Medline]
activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J. Immunol. 158:614.[Abstract]
, STAT1, and TGF-ß-regulated expression of the class II transactivator gene. J. Immunol. 160:233.
. J. Exp. Med. 182:1793.
-activated SJL/J astrocytes. J. Immunol. 160:4271.This article has been cited by other articles:
![]() |
R. Arakaki, A. Nagaoka, N. Ishimaru, A. Yamada, S. Yoshida, and Y. Hayashi Role of Plasmacytoid Dendritic Cells for Aberrant Class II Expression in Exocrine Glands from Estrogen-Deficient Mice of Healthy Background Am. J. Pathol., May 1, 2009; 174(5): 1715 - 1724. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Jiang, Y. Ke, D. Sun, G. Han, H. J. Kaplan, and H. Shao Reactivation of Uveitogenic T Cells by Retinal Astrocytes Derived from Experimental Autoimmune Uveitis-Prone B10RIII Mice Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 282 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tezel, X. Yang, C. Luo, Y. Peng, S. L. Sun, and D. Sun Mechanisms of Immune System Activation in Glaucoma: Oxidative Stress-Stimulated Antigen Presentation by the Retina and Optic Nerve Head Glia Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 705 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. C. Hornell, G. W. Beresford, A. Bushey, J. M. Boss, and E. D. Mellins Regulation of the Class II MHC Pathway in Primary Human Monocytes by Granulocyte-Macrophage Colony-Stimulating Factor J. Immunol., September 1, 2003; 171(5): 2374 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Y. Dietrich, P. R. Walker, and P. Saas Death receptors on reactive astrocytes: A key role in the fine tuning of brain inflammation? Neurology, February 25, 2003; 60(4): 548 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. De Keyser, E. Zeinstra, and E. Frohman Are Astrocytes Central Players in the Pathophysiology of Multiple Sclerosis? Arch Neurol, January 1, 2003; 60(1): 132 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Stuve, S. Youssef, A. J. Slavin, C. L. King, J. C. Patarroyo, D. L. Hirschberg, W. J. Brickey, J. M. Soos, J. F. Piskurich, H. A. Chapman, et al. The Role of the MHC Class II Transactivator in Class II Expression and Antigen Presentation by Astrocytes and in Susceptibility to Central Nervous System Autoimmune Disease J. Immunol., December 15, 2002; 169(12): 6720 - 6732. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cornet, T. C. Savidge, J. Cabarrocas, W.-L. Deng, J.-F. Colombel, H. Lassmann, P. Desreumaux, and R. S. Liblau Enterocolitis induced by autoimmune targeting of enteric glial cells: A possible mechanism in Crohn's disease? PNAS, October 25, 2001; (2001) 231474098. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Krogsgaard, K. W. Wucherpfennig, B. Canella, B. E. Hansen, A. Svejgaard, J. Pyrdol, H. Ditzel, C. Raine, J. Engberg, and L. Fugger Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2-Mbp 85-99 Complex J. Exp. Med., April 17, 2000; 191(8): 1395 - 1412. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Soos, T. A. Ashley, J. Morrow, J. C. Patarroyo, B. E. Szente, and S. S. Zamvil Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production Int. Immunol., July 1, 1999; 11(7): 1169 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cornet, T. C. Savidge, J. Cabarrocas, W.-L. Deng, J.-F. Colombel, H. Lassmann, P. Desreumaux, and R. S. Liblau Enterocolitis induced by autoimmune targeting of enteric glial cells: A possible mechanism in Crohn's disease? PNAS, November 6, 2001; 98(23): 13306 - 13311. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Girvin, K. B. Gordon, C. J. Welsh, N. A. Clipstone, and S. D. Miller Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells Blood, May 15, 2002; 99(10): 3692 - 3701. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |